Biocartis

Biotech & Life Sciences · Mechelen, Belgium · Founded 2007 · IPO 2015

Biocartis is a pioneering molecular diagnostics company dedicated to transforming molecular testing through its unique IdyllaTM platform. The company provides advanced diagnostic solutions designed to improve clinical practice for patients, clinicians, payers, and the broader healthcare industry. Biocartis operates in the molecular diagnostics market, focusing on oncology and infectious diseases. Its primary clients include hospitals, laboratories, and healthcare providers who require rapid and accurate diagnostic results. The business model revolves around the sale of diagnostic instruments and consumables, generating revenue through the continuous use of its proprietary platform and assays. Biocartis makes money by selling its IdyllaTM platform and associated diagnostic tests, which offer quick and reliable results, thereby enhancing patient care and operational efficiency in clinical settings. Keywords: molecular diagnostics, Idylla platform, oncology, infectious diseases, clinical practice, healthcare providers, rapid testing, diagnostic solutions, proprietary technology, patient care.

Valuation $170M

Revenue $52M

Total funding $100–500M

Power Law Colt$25–100M revenue

Investors

12 investors on Biocartis's cap table

Sourced from Dealroom's funding history.

Seed 1 investor entered at this stage

VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen

Series A 5 investors entered at this stage

Aescap

Advent Venture Partners

Johnson & Johnson Development Corporation

KBC

Debiopharm Group

Series B+ 6 investors entered at this stage

Wellcome Trust

PMV

Korys

RMM

Philips

Hitachi Chemical Diagnostics

Global footprint

Where Biocartis has talent and traffic

Workforce by country

19 countries with
team presence

🇧🇪 Belgium70.5%

🇺🇸 United States13.3%

🇩🇪 Germany2.9%

🇮🇹 Italy2.5%

🇫🇷 France2.5%

Top 5 of 19 shown

Web traffic by country

9.1K monthly visits
across markets

🇹🇼 Taiwan28.6%

🇧🇪 Belgium23.1%

🇺🇸 United States22%

🇪🇸 Spain17.6%

🇵🇱 Poland4.4%

Top 5 markets shown

Talent graph

The shape of Biocartis's talent

Dealroom maps Biocartis's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org

4 AI specialistsincl. 1 core researchers

311 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Biocartis's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Biocartis

An AI-synthesized read of the highest-engagement posts about Biocartis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biocartis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles